KDR and neoplasm: Both apatinib and lenvatinib are multi-target TKIs; the former can inhibit vascular endothelial growth factor receptor (VEGFR)-2 highly selectively (15), and the latter can inhibit VEGFR-1–3, FGFR1–4, platelet-derived growth factor receptor (PDGFR)-α, stem cell factor receptor (KIT), glial cell-derived neurotrophic factor receptor (RET), and other tumor-related targets (16, 17).